183 related articles for article (PubMed ID: 22037316)
1. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K; Sill MW; Darcy KM; Rubin SC; Mannel RS; Waggoner S; Schilder RJ; Cai KQ; Godwin AK; Alpaugh RK
Gynecol Oncol; 2011 Oct; 123(1):19-26. PubMed ID: 21752435
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Chen X; Darcy KM; Decesare SL; Lewandowski G; Lee RB; Arciero CA; Wu H; Godwin AK
Clin Cancer Res; 2005 Aug; 11(15):5539-48. PubMed ID: 16061871
[TBL] [Abstract][Full Text] [Related]
5. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
7. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Schilder RJ; Brady WE; Lankes HA; Fiorica JV; Shahin MS; Zhou XC; Mannel RS; Pathak HB; Hu W; Alpaugh RK; Sood AK; Godwin AK
Gynecol Oncol; 2012 Oct; 127(1):70-4. PubMed ID: 22710075
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
Gynecol Oncol; 2017 Nov; 147(2):283-290. PubMed ID: 28802766
[TBL] [Abstract][Full Text] [Related]
11. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
[TBL] [Abstract][Full Text] [Related]
12. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Martin LP; Sill M; Shahin MS; Powell M; DiSilvestro P; Landrum LM; Gaillard SL; Goodheart MJ; Hoffman J; Schilder RJ
Gynecol Oncol; 2014 Mar; 132(3):526-30. PubMed ID: 24361733
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
20. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
